Overslaan en naar de inhoud gaan
  • Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth
  • RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribers
  • Joenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake
  • Second quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024
  • Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ pathway hyperactivity, supporting reclassification of VUS patients to APDS and suggesting up to a 100-fold increase in APDS prevalence
  • Submitted new drug application for leniolisib for the treatment of APDS in Japan
  • 2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 million
  • Overall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operations
  • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view webcast)
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren